Therefore, we assessed whether cell line collections with a BRCA1/2 mutation recapitulate this response observed in the clinic by analysing synergy data from the Genomics Drug Sensitivity in Cancer drug combination database (GDSC; Wellcome Sanger Institute) [14]. The gene discussed is BRCA1; the disease is cancer.